الفهرس 
Review of literatureOnly 14 pages are availabe for public view
 |  | from | 155 |  |  |
| | | from | 155 | | |
Abstract
Hepatocellular carcinoma is the commonest primary cancer of the liver. Incidence is increasing and HCC has risen to become the 5th commonest malignancy worldwide and the third leading cause of cancer related death. Cirrhosis is the strongest and the most common known risk factor for hepatocellular carcinoma, particularly cirrhosis related to hepatitis C virus and hepatitis B virus infections. HCC diagnosis has relied on several tools combining imaging techniques and measurement of serum AFP. The use of serum AFP in surveillance programs is still debated due to its low sensitivity for early HCC; therefore there is a strong demand by clinicians for new HCC-specific biomarkers. In the present study, a monoclonal antibody designated CK1K10 was used to identify specific cytokeratin antigen (CK1) in serum samples from HCC patients and also making Isolation and purification of 67 KDa cytokeratin antigen (CK1). ELISA technique as a simple, rapid and qualitative assay was used to detect cytokeratin antigen (CK1) in sera from hepatocellular carcinoma (HCC) patients. At the cut-off level of 0.20 µg/ml, the sensitivity for detection of cytokeratin antigen in serum samples from HCC patients was 69 % with specificity of 100 %, positive predictive value (PPV) of 100 %, negative predictive value (NPV) of 55.6 % and efficiency of 77.8 %.The cytokeratin antigen (CK1) and AFP were weakly correlated, so a simultaneous determination of both markers can improve the sensitivity to 82 %. In conclusion, the 67 kDa cytokeratin antigen (CK1) may have diagnostic potential and consequently, may be used as a biomarker for diagnosis of hepatocellular carcinoma and could serve as a valuable supplement to AFP in detection of HCC.